Today’s Research Reports on Trending Tickers: Corbus Pharmaceuticals and Imprimis Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / January 31, 2018 / U.S. markets fell sharply Tuesday for the second consecutive day. Both the Dow Jones and S&P 500 experienced their largest one day drop of 2018. The Dow Jones Industrial Average dropped 1.37 percent to close at 26,076.89, while the S&P 500 Index fell 1.09 percent to close at 2,822.43. The Nasdaq Composite Index declined 0.86 percent to close at 7,402.48. Investors appear to be awaiting details from the State of the Union address by President Donald Trump on Tuesday night.

“We’ve had a unilateral move higher [in stocks] to start things off and people are realizing this is not sustainable,” said Art Hogan, chief market strategist at B. Riley FBR. “You’re also seeing some cracks in the global story with interest rates rising.”

RDI Initiates Coverage on:

Corbus Pharmaceuticals Holdings Inc.
https://rdinvesting.com/news/?ticker=CRBP

Imprimis Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=IMMY

Corbus Pharmaceuticals stock fell 11.89% Tuesday, to close the day at $8.15. The stock recorded a trading volume of 4,306,752 shares, which was above its three months average volume of 789,806 shares. In the last year, Corbus Pharmaceuticals shares have traded in a range of 5.30 – 10.50. The share price has gained 53.77% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $7.83 is greater than its 200-day moving average of $7.06. Shares of Corbus Pharmaceuticals have gained roughly 14.79 percent in the past month.

Access RDI’s Aetna Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CRBP

On Tuesday, shares of Imprimis Pharmaceuticals recorded a trading volume of 19,711,330 shares, which was above the three months average volume of 174,822 shares. The stock ended the day 14.29% higher at 1.92 after the company reported that it will make available 2 glaucoma drugs that are now on FDA’s drug shortage list. The share price has gained 42.22% from its 52-week low with a 52-week trading range of 1.35 – 4.69. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $1.68 is below its 200-day moving average of $1.85. Shares of Imprimis Pharmaceuticals have gained roughly 12.94 percent in the past month.

Access RDI’s Imprimis Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IMMY

Our Actionable Research on Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) and Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 487452